|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/55 | |
| A61K 39/395 | |||
| A61P 35/02 | |||
| A61P 35/00 | |||
| A61K 45/06 | |||
| C07K 16/28 | |||
| C07K 16/32 |
| (11) | Patento numeris | 2560658 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11772735.4 |
| Europos patento paraiškos padavimo data | 2011-04-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-02-27 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-02-22 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/033500 |
| Data | 2011-04-21 |
| (87) | Numeris | WO 2011/133819 |
| Data | 2011-10-27 |
| (30) | Numeris | Data | Šalis |
| 326406 P | 2010-04-21 | US |
| (72) |
HERSHBERG, Robert, US
|
| (73) |
VentiRx Pharmaceuticals, Inc.,
1191 Second Avenue, Suite 1105, Seattle, WA 98101,
US
|
| (54) | ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| ENHANCING ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |